RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
South Korea’s Kolon Life Science signed a $207 million contract to export its osteoarthritis drug, Invossa-K, to China Life Medical Centre in Hainan Province. Invossa-K, the world’s first gene therapy treatment for osteoarthritis, was approved by Korea’s health authorities in July 2017. Hainan Province, an island off China’s southwest coast, is China’s center for medical tourism. The area can dispense drugs and use medical devices without the approval of Chinadrug regulators. As part of the deal, China Life Medical will conduct clinical tests of Invossa-K for mainland China approval.
Source: China Biotoday